Growth hormone (GH) secretory patterns were studied in a patient with ectopic growth hormone releasing factor (GRF) secretion and in normal men given continuous infusions of human growth hormone releasing factor (1-40)-OH (hGRF-40). In the patient with ectopic GRF secretion, GH secretion was pulsatile despite continuously elevated immunoreactive GRF levels. To determine if pulsatile GH secretion is maintained in normal subjects, we administered to six healthy young men vehicle or hGRF-40, 2 ng/kg per min, for 24 h and gave a supramaximal intravenous bolus dose of hGRF-40, 3.3 Aig/kg, after 23.5 h of infusion. hGRF-40 infusion resulted in greater GH secretion than did vehicle infusion and pulsatile GH secretion was maintained throughout hGRF40 infusion. During the 23.5 h of vehicle infusion, total GH secretion (microgram; mean±SEM) was 634±151 compared with 1,576±284 during hGRF-40 infusion (P = 0.042). The GH response to the intravenous bolus of hGRF-40 was greater after vehicle infusion than after hGRF-40 infusion; 877±170 and 386±125 ,ug of GH was secreted after the bolus on vehicle and hGRF-40 days, respectively (P = 0.015). The total amount of GH secreted during the 25.5 h of the two study days was not different; 1,504±260 and 1,952±383 1g were secreted during vehicle and hGRF40 days, respectively (P = 0.36). Not only was pulsatile GH secretion maintained during hGRF40 infusion, but there was augmentation of naturally occurring GH pulses, which is in contrast to the effect of gonadotropin-releasing hormone on gonadotropin secretion. We suggest that GH pulses are a result of GRF secretion that is associated with a diminution or withdrawal of somatostatin secretion.
Introduction
In order to determine the effects of prolonged exposure of the somatotroph to growth hormone releasing factor (GRF),' we 1. Abbreviations used in this paper: GH, growth hormone; GnRH, gonadotropin-releasing hormone; GRF, growth hormone releasing factor; hGRF-40, human growth hormone releasing factor (1-40)-OH; LH, luteinizing hormone; rGRF, rat GRF.
report a patient with acromegaly secondary to ectopic GRF production and the results of 24-h human growth hormone releasing factor (1-40)-OH (hGRF-40) infusions in normal men.
Synthetic hGRF-40 and hGRF-44 specifically stimulate growth hormone (GH) release by the anterior pituitary gland in normal men (1) (2) (3) . During infusions of incremental doses of hGRF-40, 1, 3.3, 10, and 33 ng/kg per min, each for 90 min, there appears to be a dose-related increase of GH secretion during the l-10-ng/kg per min infusions. During the 33-ng/kg per min dose, the effect wanes (4) . However, there is great variability in the magnitude and timing of the GH responses among subjects. To determine whether this variability is related to the incremental manner of administration of hGRF-40, we performed a second series of studies in which normal subjects were given 6-h infusions of vehicle or hGRF-40, 1, 3.3, and 10 ng/kg per min on separate occasions (5) . In these experiments, the maximal GH response was observed during the 3.3-ng/kg per min infusion, but there was great variability in the GH responses among and within subjects. In addition, 30 min before the end of the 6-h infusion each subject received a supramaximal bolus injection of 3.3 gg/kg of hGRF-40. The amount of GH released in response to the bolus was inversely proportional to the dose of hGRF-40 given during the infusion. These results suggested that, within the limitations of this experimental paradigm, GH secretion is pulsatile throughout 6 h of stimulation by hGRF-40 and a defined amount of GH is available for release. We now report our findings in a patient with ectopic GRF secretion and the nature of GH responsiveness in normal men during administration of hGRF-40, 2 ng/kg per min, continuously over 24 h with an additional intravenous bolus injection of 3.3 ,ug/kg after 23.5 h of infusion. The pattern of GRF and GH secretion in the patient with ectopic GRF secretion and our observations in normal men support the hypothesis that GH secretion is a result of the interaction of GRF and somatostatin, and indicate that the somatotroph does not become completely refractory to continuous stimulation by GRF.
Methods
Case report. W.K. is a 48-yr-old man with acromegaly secondary to ectopic production of GRF from a metastatic carcinoid tumor. He underwent a left lower lobectomy in 1963 for an asymptomatic lesion that proved to be a carcinoid tumor. Over the intervening 20 yr he had signs of progressive acromegaly (i.e., acral enlargement, excessive sweating, widening of teeth spaces). In 1982 he underwent a right total hip replacement for presumed degenerative joint disease. Microscopic examination of the femoral head revealed metastatic carcinoid cells. He was initially seen at the University of Virginia in 1983 for evaluation of acromegaly and possible ectopic GRF production. His only pertinent medical history was a progressive increase in shoe and ring size and dental malocclusion. Physical examination was remarkable for a definite acromegalic appearance: normal blood pressure, dental braces, and minimal impairment of range of motion in the right hip.
Endocrine evaluation revealed normal levels of serum thyroxine (10.0 Mg/dl; normal 4.5-11.5), thyroid-stimulating hormone (1.5 M4U/ ml; normal < 4), prolactin (11.7 ng/ml; normal < 20), testosterone (444 ng/ml; normal 300-1,000), luteinizing hormone (LH) (8.1 mIU/ ml; normal 7.9-18.1), follicle-stimulating hormone (9.0 mIU/ml; normal 1.2-22.6), and morning plasma cortisol (10 Mg/dl; normal 7-25). The serum somatomedin C was elevated at 5.2 U/ml (normal 0.62-1.79) as was the serum GH at 22 ng/ml (mean of 21 determinations through the day). A plasma immunoreactive GRF level was 11.3 ng/ml (normal < 600 pg/ml). After intravenous thyrotropin-releasing hormone, 500
Mg, the serum GH rose from a baseline of 24 to a peak of 169 ng/ml. (1, 2) . The peptide solution was diluted with normal saline and administered in a dose of 2 ng/kg per min.
The studies were approved by the Food and Drug Administration and the Human Investigation Committees of the University of Virginia and the Salk Institute. Having given informed written consent, six healthy men, ages 20-32 yr (mean 26 yr), were studied. All subjects were within 15% of ideal body weight, had no medical problems, and took only ferrous sulfate between the study periods. Each subject was studied on two occasions which were separated by at least 30 d. They fasted from midnight until lunch, but were given water freely throughout the study. They were also given dinner at 1800 h and a snack at 2100 h. The subjects remained recumbent during the study, awake during the day, and were permitted to sleep through the night. Tobacco was not used during the studies. Blood pressure, pulse rate, and temperature were measured every hour from 0800 to 2200 h and from 0600 h the next morning until the end of the study at 1200 h. Blood samples for GH determinations were drawn every 15 min from 0800 h on the first study day until 1200 h the following day (total of 112 samples). Specimens for somatomedin C determinations were drawn at 0800 and 1800 h on the first day, at 0800 h the second day, and at 1000 h on the third day.
The protocol consisted of a control day (vehicle) and a hGRF-40 day in which normal saline was infused for the first 2 h (0800-1000 h), and was followed by a 24-h infusion of either vehicle or hGRF-40, 2 ng/kg per min. After 23.5 h of infusion, the subjects were given an intravenous bolus injection of hGRF-40, 3 .3 ug/kg (0930 h, second day). From 1000 until 1200 h on the second day saline was again infused. The infusions were administered with a Harvard pump (Harvard Apparatus Co., Millis, MA). The total volume of infusate was 43 ml over 28 h.
Assays. Serum GH and somatomedin C were measured by standard radioimmunoassay (RIA) as described previously (7, 8) . The sensitivity of the GH assay was 0.05 ng/tube. At 5 ng/ml the intraassay coefficient of variation was 11.5%. The intraassay variation for the somatomedin C assay was 5.8% at 0.3 U/ml and 6.6% at 1.22 U/ml. All samples from each subject were measured in the same assay to avoid interassay variation. Plasma GRF determinations were made by collection of 4'/2 ml of blood into plastic syringes that were kept at 4VC before blood drawing and the samples were immediately placed into heparincontaining tubes with 0.2 ml of aprotonin (Trasylol, 10,000 kallikrein inhibiting units/ml). The samples were immediately centrifuged at 4VC and the plasma removed and frozen. We have previously demonstrated that this method of collection prevents degradation of '251-hGRF-40 for at least 24 h at 40C and at least 2 h at 370C (9) . In the absence of aprotonin, >10% degradation was noted at 6 and 1 h, respectively. The recoveries of exogenous hGRF-40 added to plasma treated with aprotonin were 99±6%. The plasma GRF RIA used unextracted plasma (10) . Each plasma sample was assayed in at least two different dilutions, and in the present experiment, shown in Fig. 2 , 10, 20, 50, 80, or 100 Ml of plasma was added to each assay tube, and this was performed in duplicate. The volume of incubation was kept constant by varying the amount of buffer added.
hGRF-40 (synthesized as previously described [1] ) was radioiodinated by the chloramine-T method as previously described (10 
Results
Acromegaly secondary to ectopic GRF production. In Fig. 1 , both GH and immunoreactive GRF levels during a 24-h period are shown. GRF levels were in the 5-30 ng/ml range (mean 11.3 ng/ml; mean of 71 determinations) throughout the 24 h of the study. These levels are an order of magnitude above minimum levels of GRF necessary to stimulate GH secretion in normal subjects after infusion of hGRF-40 (9 Normal subjects. Spontaneous pulses of GH occurred in all subjects during the control (vehicle) day. These increases, which were more prominent during the night, are shown in Figs. 3 and 4 . The GH levels between pulses were low (usually <0.5 ng/ml) on both vehicle and hGRF-40 days and the GH pulses were greater during hGRF-40 infusion than during vehicle infusion. Visual inspection of the data suggested a temporal relationship between the GH pulses on the vehicle and hGRF-40 days in that most of the increases occurred at the same times during both study days, particularly during the early hours of sleep. These patterns are suggestive of augmentation of naturally occurring GH surges by hGRF-40.
Review of individual subject responses to hGRF-40 and vehicle infusions (Fig. 3) When expressed as total GH secreted (microgram), there was no difference between the vehicle and hGRF-40 days during the initial 2 h of saline infusion (P = 0.50) (Fig. 5) . Total GH secreted during the 23.5 h of hGRF-40 infusion was 2.5-fold greater than during the vehicle infusion (P = 0.015). Total GH secreted (mean±SEM) during the 2.5 h after the bolus injection of hGRF-40 was 877±170 1Ag on the vehicle day and 386±125 ;tg on the hGRF-40 day (P = 0.042, vehicle vs. hGRF-40 day). The quantity of GH secreted during the two study periods, i.e., continuous infusion and after intravenous bolus injection, was not different on the vehicle and hGRF-40 days (P = 0.36).
Changes in serum somatomedin C levels during (22 h) and 48 h after the infusion were not different between the vehicle and hGRF-40 days (P > 0.05). When changes in levels were compared with preinfusion levels on the same study day, there was a significant increase in somatomedin C levels only after 22 h of hGRF-40 infusion (Table I ; P = 0.035). Somatomedin C levels were greater in five of five subjects 48 h after the hGRF-40 infusion (24 h after the intravenous bolus injection), but this did not reach the level of statistical significance and thus indicates only a trend (P = 0.059).
Discussion
Growth hormone secretion is regulated by the stimulatory peptide, growth hormone releasing factor, and the inhibitory peptide, somatostatin. The interaction of these peptides is likely a complex one and is not yet fully understood. GRF secreting tumors are associated with clinical acromegaly, thus suggesting that the somatotroph can be continuously stimulated to secrete excessive quantities of GH (6) . However, the pattern of GH secretion in this disorder is not known, while in normal men GH secretion is pulsatile. Our studies were designed to observe the pattern of GH secretion in a patient with a GRFsecreting tumor and determine whether GH secretion was constant or pulsatile. In this patient we observed that his GH secretion was pulsatile. The pattern of GH secretion, while pulsatile, was abnormal in that there was no rise in GH during the period 2400-0500 h. This may represent an alteration of the normal circadian rhythm in this patient. This to normal men under control conditions and two and onehalf times that of normal men given hGRF-40 (i.e., -4.2 mg vs. -0.7 and 1.6 mg, respectively). We measured this patient's plasma immunoreactive GRF levels to determine whether the pulsatile pattern of GH secretion was influenced by changing circulating GRF levels, or alternatively, by varying pituitary responsiveness. Although the immunoreactive GRF levels did vary, they only accounted for 6% of the variation in GH secretion. In addition, the minimum levels observed (5 ng/ml) were 10-20-fold greater than the minimum levels we have observed that stimulate GH secretion in normal subjects (i.e., 300 pg/ml) (4) . We calculated that this tumor secretes -4 mg of GRF per day, and thus this patient was exposed to the equivalent of a continuous infusion of GRF at a dose in excess of 28 ng/kg per min.
We next examined the effects of a 24-h continuous infusion of hGRF-40 in normal young men. These studies demonstrated that the peptide stimulated GH release and augmented the naturally occurring pattern of GH secretion, particularly during the usual time of maximal GH secretion, i.e., during early morning hours of sleep. This pattern of GH secretion is different from that observed with gonadotropin secretion in subjects given gonadotropin-releasing hormone (GnRH) infusions. Infusion of GnRH results in biphasic release of LH and follicle-stimulating hormone with failure to return to base-line levels until apparent depletion or desensitization has occurred Pulsatile Growth Hormone Secretion during 24 produced by the infusion. We believe this is unlikely based upon our previous infusion studies in which we were able to demonstrate GH stimulation at a dose of 1.0 ng/kg per min (4) . Similarly, the pattern of GH secretion observed in our patient with ectopic GRF secretion, in whom the GRF levels were extremely high throughout, would make this explanation unlikely. Rather, the preserved rhythmicity is more likely the result of the intermittent withdrawal of tonic inhibition of GH secretion by hypothalamic somatostatin. Peripheral somatostatin levels do not reflect changes in hypothalamohypophyseal portal concentrations. We have observed no changes in peripheral somatostatin levels after hGRF-40 administration (1, 2) . These findings are consistent with the hypothesis that changes in hypothalamic and/or pituitary somatostatin concentrations are responsible for preservation of intermittent pulsatile GH secretion during hGRF-40 infusion. The elegant in vivo studies of Tannenbaum and Ling (16) (24) . Thus, it is quite possible that GH feedback contributes to the reduced response of the supramaximal intravenous bolus injection, but this is likely mediated through somatostatin. Another candidate for negative feedback is somatomedin C. Administration of somatomedin C to unanesthetized rats suppresses GH secretion (20) . In man, GH administration results in a rise in serum somatomedin C levels after 6 to 8 h (25) . In our studies in normal subjects, small increases in serum somatomedin C levels after 22 h of hGRF-40 infusion were observed. Despite these increases, GH pulses occurred as late as 23.5 h into the infusion of hGRF-40. Additionally, the acromegalic patient had serum somatomedin C levels that were at least threefold elevated, and intermittent pulsatile GH secretion was preserved. These data suggest that somatomedin C is more likely to act to alter the set point for GH secretion instead of directly affecting pulsatile secretion, and is therefore unlikely to have contributed to the reduced response to the supramaximal dose of GRF administered at 23.5 h into the hGRF-40 infusion. Based on our observations in the acromegalic patient with ectopic GRF secretion and the results of 24-h infusions of hGRF-40 in normal young men, we suggest that GH secretion in man is regulated by the dynamic interaction of GRF and somatostatin, and that, in the absence of blockade of the secretion of or effects of somatostatin, the somatotroph is capable of responding to prolonged GRF stimulation without becoming either depleted of total GH or completely refractory to this stimulus. These observations are not only of physiological importance, but may also be important in the design of therapy with GRF. In addition, our observations complement those of Tannenbaum and Ling (16) in the rat and offer support to the concept that pulsatile GH secretion in man is likely caused by a combination of enhanced GRF secretion with concomitant reduction of somatostatin secretion. 
